default author photo

Harry C. Schouten

Maastricht University, Medical Center, Department of Hematology

Netherlands

SCHOLARLY PAPERS

1

DOWNLOADS

116

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

No Benefit of Rituximab in Primary Central Nervous System Lymphoma Patients: Results of the Randomised Phase III HOVON 105 / ALLG NHL 24 Intergroup Study

Number of pages: 92 Posted: 19 Sep 2018
Erasmus University Rotterdam (EUR) - Department of Neuro-Oncology, Counties Manukau District Health Board - Middlemore Hospital, Erasmus University Rotterdam (EUR) - HOVON Data Center, Utrecht University, University Medical Center, Cancer Center, Department of Hematology, Utrecht University - Department of Neurology, Elisabeth-Tweesteden Hospital, Sir Charles Gairdner Hospital, Maastricht University, Medical Center, Department of Hematology, Radboud University Nijmegen - Department of Hematology, VU University Amsterdam - Department of Hematology, Netherlands Cancer Institute, University of Groningen - Department of Hematology and Oncology, University of Melbourne - Royal Melbourne Hospital, Spaarne Gasthuis, Erasmus University Rotterdam (EUR) - Department of Neuro-Oncology, University of Groningen, University of Melbourne - Royal Melbourne Hospital, VU University Amsterdam and Erasmus University Rotterdam (EUR) - Department of Hematology
Downloads 116 (613,149)

Abstract:

Loading...

Rituximab, PCNSL, Primary Central Nervous System Lymphoma treatment